CD155, also called PVR, stands at a biologically interesting interface between tumor and immune cells. Among others, it interacts with the inhibitory immune receptor TIGIT and the activating receptor CD226. The spatial visualization of CD155 together with further immune cell markers can therefore be of particular interest for research projects on the TIGIT axis and the tumor microenvironment.
Where the project stands today
Jürgen Frerichs initiated the production of antibody clones against CD155. ONCOdianova has invested in this development. This production has yielded 17 CD155 candidate clones that are now available for the next scientific development phase.
In the next step the 17 clones are to be examined experimentally in stages. The aim is to identify suitable candidates and then to characterize them in more detail on selected control and tumor tissues.
In this way an early candidate can become a research reagent that can be used reproducibly for a clearly defined tissue-based application.
Scientific development partner sought
ONCOdianova is looking for an experienced research group, a pathology laboratory or a development partner already working on CD155, the TIGIT axis, the tumor microenvironment or related questions.
Partners who have human FFPE tissue, suitable controls, an established IHC or multiplex platform and experience in the comparative evaluation of new antibody clones are particularly welcome.
ONCOdianova contributes the 17 existing CD155 candidate clones and the scientific exchange to the collaboration. The further experimental screening, optimization and validation is carried out by the development partner, self-funded and at its own development risk. ONCOdianova does not assume any laboratory, validation or development costs for this next development phase.
This can include the comparative screening of the clones, the development of suitable experimental conditions, the examination of control and tumor tissues and the comparison with established research reagents.
The clones remain with ONCOdianova.
Scientific and commercial perspective
The partner has the opportunity to work with the CD155 candidates at an early stage and to help shape the scientific direction of the characterization.
A scientific publication of suitable results is expressly welcome. Authorship and scientific credit follow the actual contribution of those involved and the rules of the respective journal.
If the collaboration produces a scientifically and economically valuable clone, a success-based economic participation can be agreed with the development partner. Depending on the partner's contribution and the joint agreement, this can relate to the clone concerned or to revenues generated from it.
The scope and conditions of the collaboration, the rights to the results, the scientific publication, the use of the materials provided and any economic participation are agreed individually and in writing before the relevant development phase begins.
You already work with CD155, TIGIT or human FFPE tumor tissue and would like to help develop an early CD155 candidate scientifically? Then we look forward to a confidential conversation.
Early research and development project. The suitability of the 17 clones for the intended application is the subject of the planned scientific evaluation. For research use only.